NexACT - A New Drug Delivery Platform
NexMed's drug delivery technology - NexACT - represents an important breakthrough in providing a highly effective transdermal therapeutic approach to the diseases that are currently being treated by systemic (oral or intravenous injections) therapy. The patented NexACT technology utilizes highly effective formulations containing new biodegradable ingredients to overcome the skin's natural barrier properties and enables the rapid penetration of high concentrations of active drug directly through the skin and major mucous membranes, thereby resulting in new and highly effective topical and transdermal therapies. The rationale for developing a transdermal drug product is multifaceted. NexACT technology may offer significant clinical benefits if low bioavailability, multiple daily dosing, liver first pass effect, or gastrointestinal side effects are associated with oral or injectable dosage forms. For drugs with narrow therapeutic index, NexACT technology may provide a controlled rate of administration which is a significant advantage for maintaining efficacy while reducing toxicity. Using differential scanning calorimetry, NexACT technology is suggested to enhance drug transfer by interacting with the polar region of the phospholipid bilayer and also by increasing the motional freedom of lipid hydrocarbon chains. The cellular mechanism of action of NexACT technology is shown to increase the permeability of cell membrane in a time and concentration dependent manner. Novel application of NexACT technology for transcellular drug delivery is under development.
Commercial Potential
The NexACT platform technology can be applied to dramatically improve the absorption of active therapeutic ingredients and/or to develop new patient-friendlier routes of administration. Incorporating older drugs with the NexACT proprietary delivery system can create new products that not only provide patients with added therapeutic benefits, but also extend the product life for up to an additional 20 years under the multiple patent protection of the NexACT technology.
More than $150 billion in brand-name drug products are coming off patent between 2010 and 2015. This represents a significant opportunity for converting some of those products from injectable or oral dosage forms into topical forms for better patient compliance or for added therapeutic benefit.
NexMed Intellectual Property
Patents and other proprietary rights are essential to our business. We have filed patent applications in an effort to protect our platform technology and formulations. NexMed has been issued patents on its dispenser, formulation, and proprietary drug delivery technology.
We have been awarded U.S. and foreign issued patents, with numerous patents pending. Our patents issued date back as early as 1990. Most of our patents are recently issued and have considerable patent life remaining.
